Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Conference Call March 18, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman & Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Incorporated Fourth Quarter 2023 Financial Results and Business Update Conference Call. All participants will be in listen-on ...

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Conference Call November 10, 2023 10:00 AM ET Company Participants Tirth Patel - IR Hermann Luebbert - Chairman, CEO and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the c ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2023 Commission file number 001-40943 | --- | --- | --- | |------------------------------------------------------|---------------------|-------------------------------------------------------| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common stock, par value $0.001 per share | BFRI | The Nasdaq Stock Market LLC | | Preferred Stock Pur ...

Biofrontera Inc. (NASDAQ:BFRI) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good morning everyone and welcome to the Biofrontera Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please also note ...

OR Biofrontera Inc. (Exact name of registrant as specified in its charter) FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 (Mark One) For the quarterly period ended June 30, 2023 Delaware 47-3765675 (State or other jurisdiction of ...

Biofrontera Inc. (NASDAQ:BFRI) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Welcome to the Biofrontera Inc. First Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conferen ...

Financial Performance - Product revenues for Q1 2023 were $8.7 million, a decrease of $1.02 million or 10.5% compared to $9.8 million in Q1 2022, attributed to a lack of customer buy-in prior to a price increase [234]. - The company reported a net loss of $7.478 million for Q1 2023, compared to a net income of $5.561 million in Q1 2022, representing a change of $13.039 million [209]. - Adjusted EBITDA for Q1 2023 was $(3.990) million, a decrease from $(2.439) million in Q1 2022, with the adjusted EBITDA margin dropping from -25.0% to -45.7% [218]. - Operating expenses for Q1 2023 totaled $14.225 million, an increase of $1.364 million or 10.6% from $12.861 million in Q1 2022 [209]. - For the three months ended March 31, 2023, the company incurred a loss from operations of $5.5 million, compared to a loss of $3.1 million for the same period in 2022 [243]. - The company experienced net cash outflows from operations of $3.7 million for the three months ended March 31, 2023, compared to $2.1 million for the same period in 2022 [243]. - The company reported net cash used in operating activities of $3.7 million for the three months ended March 31, 2023, compared to $2.1 million for the same period in 2022 [249]. - As of March 31, 2023, the company had an accumulated deficit of $87.0 million [243]. Cash and Financing - Cash and cash equivalents as of March 31, 2023, were $13.5 million, down from $17.2 million as of December 31, 2022 [219]. - The company anticipates needing additional equity or debt financing to support long-term growth and mitigate operational cost risks [221]. - The company is expecting to collect a receivable of $3.7 million from Biofrontera AG for reimbursement of legal settlement payments [246]. Cost Management - The cost of revenues related to products was $4.547 million in Q1 2023, down 8.6% from $4.975 million in Q1 2022, driven by decreased Ameluz product revenue [211]. - The company expects to continue incurring operating losses due to significant discretionary sales and marketing efforts as it seeks to expand the commercialization of its licensed products in the U.S. [244]. - The company anticipates additional expenses to improve operational, financial, and information systems, as well as to support product commercialization efforts [244]. Market and Operational Outlook - The company plans to expand sales of Ameluz in the U.S. and aims to position it as the standard of care for treating actinic keratoses [199]. - The company continues to monitor the impact of the COVID-19 pandemic on its operations, with optimism for recovery following the end of the Public Health Emergency on May 11, 2023 [200]. Fair Value Adjustments - The fair value of contingent consideration related to the acquisition of Cutanea products was determined to be $6.5 million at acquisition and is re-measured at each reporting date [213]. - The change in fair value of warrant liabilities decreased by $7.7 million for the three months ended March 31, 2023, driven by changes in the underlying value of the common stock [236]. - The change in fair value of investments in equity securities decreased by $2.9 million, influenced by changes in the quoted market price of Biofrontera AG's common stock [237]. Definitions - The adjusted EBITDA margin is defined as adjusted EBITDA expressed as a percentage of revenues for the period [242].

Biofrontera, Inc. (NASDAQ:BFRI) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Erica Monaco - CEO, COO, Treasurer & Secretary Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Bruce Jackson - The Benchmark Company Operator Greetings and welcome to the Biofrontera, Inc. Fourth quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the form of presentation ...

Biofrontera, Inc. (NASDAQ:BFRI) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Tirth Patel - LHA Investor Relations Fred Leffler - CFO Erica Monaco - CEO, COO, Treasurer & Secretary Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter Earnings Conference Call. [Operator Instructions]. Please note, this event is being recorded. I would now like to tu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share BFRIW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...